4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$5.73 USD
-0.32 (-5.29%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.66 -0.07 (-1.22%) 6:14 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, 4D Molecular Therapeutics, Inc. has a market cap of $280.26M, which represents its share price of $6.05 multiplied by its outstanding shares number of 46.33M. As a small-cap company, FDMT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
FDMT 5.73 -0.32(-5.29%)
Will FDMT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Other News for FDMT
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | FDMT ...
12 Health Care Stocks Moving In Monday's Intraday Session
FDMT Stock: Analyst Chardan Capital Maintains Buy Rating at $25 | FDMT Stock News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket